Other News

RapidPulse Launches With $15 Million Series A Financing for Ischemic Stroke Therapy

Industry Veterans Join Team to Support the Development of Novel Cyclic Aspiration System for Ischemic Stroke MIAMI, June 23, 2021 (GLOBE NEWSWIRE) — RapidPulse, Inc., a privately-held medical device company developing a novel aspiration system to treat ischemic stroke, today announced the closing of a $15 million Series A financing. […]

CardioFocus Receives Regulatory Approval to Market HeartLight X3 System in Japan

– Japan Lifeline will distribute CardioFocus’ innovative catheter ablation technology for pulmonary vein isolation, the gold standard treatment for atrial fibrillation – Regulatory approval comes as use of catheter ablation technologies for AFib is increasing in Japan at a substantial rate MARLBOROUGH, Mass., June 23, 2021 /PRNewswire/ — CardioFocus, Inc., a medical device […]

PREFECT Trial Outcomes Demonstrate MyoStrain® Ability to Detect & Predict Early Cardiotoxicity in Cancer Patients Undergoing Chemotherapy

MORRISVILLE, N.C., June 23, 2021 /PRNewswire/ — A new pivotal article validated Myocardial Solutions technology MyoStrain® (fSENC) for the early detection and prediction of cardiotoxicity (heart damage). The article was published in Circulation: Cardiovascular Imaging and highlights MyoStrain as an accurate and sensitive management tool that may help clinicians protect cancer patient heart health during […]

JanOne Readies Clinical Supply of Lead Product Candidate JAN101 for Distribution to Phase 2b Trial Sites

Company Fully Prepared to Commence Phase 2b Trials of JAN101 for Peripheral Artery Disease (PAD) as Soon as New Protocol is Approved by the FDA LAS VEGAS, June 23, 2021 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), a company focused on developing treatments for conditions that cause severe pain and drugs with non-addictive, pain-relieving properties, […]

InCarda Therapeutics Announces Positive End-of-Phase 2 Meeting with FDA for InRhythm™ for Treatment of Atrial Fibrillation

Single Pivotal Phase 3 Trial in Atrial Fibrillation Acceptable to Support Filing of New Drug Application Company on Track to Initiate Phase 3 RESTORE1 Study in Q3 2021 with Data Expected 2H 2022 SAN FRANCISCO, June 23, 2021 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing […]

CentraCare First in World to Use 4D Hologram Technology to Successfully Complete Structural Heart Procedure

EchoPixel’s pre-planning and intra-operative technologies reduced complex heart procedure time while improving quality of outcomes ST. CLOUD, Minn., June 23, 2021 (GLOBE NEWSWIRE) — CentraCare, one of the largest health systems in Minnesota, has successfully completed the first structural heart procedure in the world using 4D hologram technology, which was developed […]

BioCardia Announces Fourth Positive DSMB Review and Recommendation to Continue Phase III Pivotal CardiAMP Cell Therapy Heart Failure Study as Designed

SAN CARLOS, Calif., June 23, 2021 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary disease, today announces that the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the Phase III pivotal CardiAMP™ […]

Andrew Hotchkiss joins Draupnir Bio as Chief Executive Officer

Copenhagen and Aarhus, Denmark, 23 June 2021 – Draupnir Bio (“Draupnir”), a biotechnology company developing small molecule modulators of PCSK9 to transform the treatment of heart disease, today announces the appointment of Andrew Hotchkiss as Chief Executive Officer (CEO). Andrew brings more than 30 years of global experience in the pharmaceutical and biotechnology industries. He joins […]